NCT03396874View on ClinicalTrials.gov

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

PHASE2CompletedINTERVENTIONAL
Enrollment

1,435

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

August 9, 2022

Study Completion Date

August 9, 2022

Conditions
Prostate CancerProstate AdenocarcinomaProstate Cancer MetastaticProstate Cancer Recurrent
Interventions
DRUG

68Ga-PSMA

"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT03396874 - Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | Biotech Hunter | Biotech Hunter